On the Time to Conclusion of Phase II Cancer Clinical Trials and Its Application in Trial Designs

被引:0
作者
Lu, Ying [1 ,2 ]
Fan, Sheng-Hua Kelly [3 ]
机构
[1] Palo Alto VA Cooperat Studies Program Coordinatin, Mountain View, CA 94043 USA
[2] Stanford Univ, Dept Hlth Res & Policy, Sch Med, Stanford, CA 94305 USA
[3] Calif State Univ E Bay, Dept Stat & Biostat, Hayward, CA 94542 USA
来源
STATISTICS IN BIOPHARMACEUTICAL RESEARCH | 2012年 / 4卷 / 04期
关键词
Monte Carlo simulation; Optimal design; Phase II cancer trials; Trial duration; Two-stage design; 2-STAGE DESIGNS; STATISTICAL-METHODS; SINGLE-ARM; THERAPY; GUIDELINES; FUTURE;
D O I
10.1080/19466315.2012.695258
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Most phase II cancer trials evaluate total response (TR) rate using a single-arm open-label design. Simon's two-stage design minimizes either the expected or the total number of patients. In this article, we investigate the distribution of time to reaching trial conclusion (TRTC) of such two-stage trials, which considers the accrual rate, time to TR, futility, and efficacy decision rules. We develop a Monte Carlo algorithm for the distribution of TRTC for both one-and two-stage phase II designs. We further propose an optimal design that balances the needs of concluding the trial within the required time period and minimizing the expected sample size. Generalized recursive formulas are derived analytically in the Appendix, which are theoretically interesting but not recommended for practical use. In conclusion, a consideration of the TRTC can lead to an optimal design with a minimum increase in the expected number of patients but an increased confidence in reaching study conclusions within the required time.
引用
收藏
页码:324 / 335
页数:12
相关论文
共 27 条
  • [1] Adaptive two-stage designs in phase II clinical trials
    Banerjee, Anindita
    Tsiatis, Anastasios A.
    [J]. STATISTICS IN MEDICINE, 2006, 25 (19) : 3382 - 3395
  • [2] Statistical methods for analyzing sequentially randomized trials
    Bembom, Oliver
    van der Laan, Mark J.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (21): : 1577 - 1582
  • [3] Blagosklonny MV, 2004, CELL CYCLE, V3, P1035
  • [4] Design and conduct of phase II studies of targeted anticancer therapy: Recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT)
    Booth, Christopher M.
    Calvert, A. Hilary
    Giaccone, Giuseppe
    Lobbezoo, Marinus W.
    Eisenhauer, Elizabeth A.
    Seymour, Lesley K.
    [J]. EUROPEAN JOURNAL OF CANCER, 2008, 44 (01) : 25 - 29
  • [5] Duration of accrual and follow-up for two-stage clinical trials
    Case, LD
    Morgan, TM
    [J]. LIFETIME DATA ANALYSIS, 2001, 7 (01) : 21 - 37
  • [6] Chen TT, 1997, STAT MED, V16, P2701, DOI 10.1002/(SICI)1097-0258(19971215)16:23<2701::AID-SIM704>3.0.CO
  • [7] 2-1
  • [8] ONE-SAMPLE MULTIPLE TESTING PROCEDURE FOR PHASE-II CLINICAL-TRIALS
    FLEMING, TR
    [J]. BIOMETRICS, 1982, 38 (01) : 143 - 151
  • [9] Clinical trial design for target-based therapy
    Fox, E
    Curt, GA
    Balis, FM
    [J]. ONCOLOGIST, 2002, 7 (05) : 401 - 409
  • [10] A modification of Simon's optimal design for phase II trials when the criterion is median sample size
    Hanfelt, JJ
    Slack, RS
    Gehan, EA
    [J]. CONTROLLED CLINICAL TRIALS, 1999, 20 (06): : 555 - 566